Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chongqing Lummy Pharmaceutical Co., Ltd.
  6. Summary
    300006   CNE100000H10

CHONGQING LUMMY PHARMACEUTICAL CO., LTD.

(300006)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2023-01-19
3.930 CNY   +0.51%
01/02Lummy Pharma Unit Gets Regulatory Nod in China for Liver Cirrhosis Drug
MT
2022Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
2022Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
 SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
01/16/2023 01/17/2023 01/18/2023 01/19/2023 01/20/2023 Date
3.91 3.86 3.87 3.91 3.93 Last
11116750 7172717 5472700 7115617 5572488 Volume
+1.82% -1.28% +0.26% +1.03% +0.51% Change
Estimated financial data (e)
Sales 2020 1 584 M 233 M 233 M
Net income 2020 -327 M -48,2 M -48,2 M
Net Debt 2020 882 M 130 M 130 M
P/E ratio 2020 -18,5x
Yield 2020 -
Sales 2021 1 225 M 181 M 181 M
Net income 2021 -101 M -14,8 M -14,8 M
Net cash position 2021 340 M 50,1 M 50,1 M
P/E ratio 2021 -67,5x
Yield 2021 -
Capitalization 4 150 M 612 M 612 M
EV / Sales 2020 4,37x
EV / Sales 2021 5,60x
Nbr of Employees 935
Free-Float 32,5%
More Financials
Company
Chongqing Lummy Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of medicines. The Company’s medicines consist of anti-infection medicines, special medicines, infusion, Chinese patent drugs and herbal decoction pieces. The Company's main products include carbon nanoparticles suspension injection, omeprazole enteric capsules, mycobacterium phlei... 
Read more
Sector
Pharmaceuticals
Calendar
03/11Earnings Release
More about the company
All news about CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
01/02Lummy Pharma Unit Gets Regulatory Nod in China for Liver Cirrhosis Drug
MT
2022Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2022Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2022Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:30000..
CI
2022Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter..
CI
2022Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year End..
CI
2021Chengdu Xindu District Cundetang Pharmacy Co., Ltd. announced that it has received $7.8..
CI
2021Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2021Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:30000..
CI
2021Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2021Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter..
CI
2021Chongqing Lummy Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2020
CI
2021Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year End..
CI
2021Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership..
CI
2021Chongqing Lummy Pharmaceutical Co., Ltd. announced that it has received CNY 1.0843315 b..
CI
More news
News in other languages on CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
01/02L'unité de Lummy Pharma obtient le feu vert réglementaire en Chine pour un médicament c..
2022Chongqing Lummy Pharmaceutical Co., Ltd. annonce ses résultats pour les neuf mois se te..
2022Chongqing Lummy Pharmaceutical Co., Ltd. annonce ses résultats pour le semestre clos le..
2022Chongqing Lummy Pharmaceutical Co., Ltd. annonce ses résultats pour le premier trimestr..
2022Chongqing Lummy Pharmaceutical Co., Ltd. annonce ses résultats pour l'année complète se..
More news
Chart CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
Duration : Period :
Chongqing Lummy Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Managers and Directors
Rong Zhao Qiu General Manager
Wen Lai Chief Financial Officer
Yuan Yuan Chairman-Supervisory Board
Jiansheng Liang Chairman
Geng Chen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CHONGQING LUMMY PHARMACEUTICAL CO., LTD.3.15%612
JOHNSON & JOHNSON-4.77%441 560
ELI LILLY AND COMPANY-4.87%330 671
NOVO NORDISK A/S0.14%309 711
ROCHE HOLDING AG-0.52%277 411
MERCK & CO., INC.-5.02%270 958